Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells

Oncogene

Volumn 34, Issue 35, 2015, Pages 4624-4634

  Starenki, D ^a   Hong, S K ^a   Lloyd, R V ^b   Park, J I ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LAMIN A; MITOGEN ACTIVATED PROTEIN KINASE; MORTALIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; PROTEIN RET; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR E2F1; TUMOR PROTEIN; UNCLASSIFIED DRUG; BCL2 PROTEIN, HUMAN; HEAT SHOCK PROTEIN 70; HSPA9 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; TP53 PROTEIN, HUMAN;

ACIDIFICATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDULLARY THYROID CARCINOMA CELL; MITOCHONDRIAL MEMBRANE; MOUSE; MTT ASSAY; NONHUMAN; ONCOGENE RET; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; UPREGULATION; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; CARCINOMA; CELL CYCLE G0 PHASE; FEMALE; GENETICS; MEDULLARY CARCINOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; THYROID TUMOR; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, MEDULLARY; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; G0 PHASE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE, NUDE; MITOCHONDRIAL PROTEINS; NEOPLASM TRANSPLANTATION; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; THYROID NEOPLASMS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84940580797     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.392     Document Type: Article

References (41)

1. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM et al. Medullary carcinoma. J Natl Compr Canc Netw 2010; 8: 512-530.
2. Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013; 98: E364-E369.
3. Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab 2012; 97: E2031-E2035.
4. Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 2013; 1: 1-8.
5. Degrauwe N, Sosa JA, Roman S, Deshpande HA. Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin Med Insights Oncol 2012; 6: 243-252.
6. Nagilla M, Brown RL, Cohen EE. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther 2012; 29: 925-934.
7. Wells SA Jr., Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134-141.
8. Daugaard M, Rohde M, Jaattela M. The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett 2007; 581: 3702-3710.
9. Deocaris CC, Widodo N, Ishii T, Kaul SC, Wadhwa R. Functional significance of minor structural and expression changes in stress chaperone mortalin. Ann NY Acad Sci 2007; 1119: 165-175.
10. Kaul SC, Deocaris CC, Wadhwa R. Three faces of mortalin: a housekeeper, guardian and killer. Exp Gerontol 2007; 42: 263-274.
11. Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddel RR et al. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 2006; 118: 2973-2980.
12. Wu PK, Hong SK, Veeranki S, Karkhanis M, Starenki D, Plaza JA et al. A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase. Mol Cell Biol 2013; 33: 4051-4067.
13. Leustek T, Dalie B, Amir-Shapira D, Brot N, Weissbach H. A member of the Hsp70 family is localized in mitochondria and resembles Escherichia coli DnaK. Proc Natl Acad Sci USA 1989; 86: 7805-7808.
14. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 2005; 205: 74-81.
15. Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR et al. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem 1998; 273: 29586-29591.
16. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R et al. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ 2011; 18: 1046-1056.
17. Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem 2005; 280: 39373-39379.
18. Iosefson O, Azem A. Reconstitution of the mitochondrial Hsp70 (mortalin)-p53 interaction using purified proteins-identification of additional interacting regions. FEBS Lett 2010; 584: 1080-1084.
19. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R et al. Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin. Int J Cancer 2011; 129: 1806-1814.
20. Wadhwa R, Yaguchi T, Hasan MK, Taira K, Kaul SC. Mortalin-MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation. Biochem Biophys Res Commun 2003; 302: 735-742.
21. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004; 204: 197-211.
22. Park JI, Strock CJ, Ball DW, Nelkin BD. The Ras/Raf/MEK/extracellular signalregulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol 2003; 23: 543-554.
23. Park JI, Strock CJ, Ball DW, Nelkin BD. Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine 2005; 29: 125-134.
24. Arthan D, Hong SK, Park JI. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Lett 2010; 297: 31-41.
25. Sosonkina N, Starenki D, Park JI. The role of STAT3 in thyroid cancer. Cancers (Basel) 2014; 6: 526-544.
26. Park JI. Growth arrest signaling of the Raf/MEK/ERK pathway in cancer. Front Biol (Beijing) 2014; 9: 95-103.
27. Sarosiek KA, Ni Chonghaile T, Letai A. Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol 2013; 23: 612-619.
28. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010; 107: 8788-8793.
29. Ryter SW, Kim HP, Hoetzel A, Park JW, Nakahira K, Wang X et al. Mechanisms of cell death in oxidative stress. Antioxid Redox Signal 2007; 9: 49-89.
30. Starenki D, Park JI. Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo. J Clin Endocrinol Metab 2013; 98: 1529-1540.
31. Mooi WJ, Peeper DS. Oncogene-induced cell senescence-halting on the road to cancer. N Engl J Med 2006; 355: 1037-1046.
32. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012; 21: 297-308.
33. Khalil AA, Kabapy NF, Deraz SF, Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta 2011; 1816: 89-104.
34. Kampinga HH, Craig EA. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat Rev Mol Cell Biol 2010; 11: 579-592.
35. Bukau B, Horwich AL. The Hsp70 and Hsp60 chaperone machines. Cell 1998; 92: 351-366.
36. Schneider HC, Berthold J, Bauer MF, Dietmeier K, Guiard B, Brunner M et al. Mitochondrial Hsp70/MIM44 complex facilitates protein import. Nature 1994; 371: 768-774.
37. Merrick BA, Walker VR, He C, Patterson RM, Selkirk JK. Induction of novel Grp75 isoforms by 2-deoxyglucose in human and murine fibroblasts. Cancer Lett 1997; 119: 185-190.
38. Starenki D, Singh NK, Jensen DR, Peterson FC, Park JI. Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice. Cancer Lett 2013; 339: 144-151.
39. Hong SK, Yoon S, Moelling C, Arthan D, Park JI. Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling. J Biol Chem 2009; 284: 33006-33018.
40. Cheng G, Zielonka J, Dranka BP, McAllister D, Mackinnon AC Jr., Joseph J et al. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res 2012; 72: 2634-2644.
41. Sosonkina N, Nakashima M, Ohta T, Niikawa N, Starenki D. Down-regulation of ABCC11 protein (MRP8) in human breast cancer. Exp Oncol 2011; 33: 42-46.